Zydus Lifesciences gets USFDA tentative approval for cancer drug ...
WEB1 day ago — Zydus Lifesciences share price will remain in focus on October 3 after the company received tentative approval from the United States Food and Drug Administration (USFDA) to manufacture ...
Zydus Lifesciences gets USFDA nod to produce prostrate cancer …
WEB23 hours ago — Zydus Lifesciences: The company has received tentative approval from the US Food and Drug Administration (USFDA) to manufacture Enzalutamide tablets (40 mg and 80 mg), the drug maker said in a regulatory filing. Enzalutamide tablets are androgen receptor inhibitors indicated for the treatment of patients with castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.
Zydus Life shares in focus today after US FDA approves cancer …
WEB4 days ago — Zydus Life shares gain 1% today after US FDA approves cancer drug worth $870 million. Zydus Lifesciences has received a significant approval from the US FDA for Enzalutamide capsules, which are ...
Zydus Lifesciences receives USFDA approval to produce prostrate …
WEB1 day ago — Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to produce a generic prostate cancer treatment drug. The company has received tentative approval from the US Food and Drug Administration (USFDA) to manufacture Enzalutamide tablets (40 mg and 80 mg), the drug maker said in a …
Zydus Receives Tentative Approval from USFDA for Enzalutamide …
WEB1 day ago — Zydus Lifesciences Limited has received tentative approval from the United States Food and Drug Administration to manufacture Enzalutamide Tablets, 40 mg and 80 mg . ... Latest news about Zydus Lifesciences Limited . Zydus Lifesciences Gets Tentative Nod from US FDA for Enzalutamide Tablets 03:26am: MT ...
Zydus Lifesciences gets USFDA nod for Ahmedabad facility
WEB2 days ago — The US health regulator inspected Zydus Lifesciences’ transdermal patch manufacturing facility in Pharmez, Ahmedabad, between July 15 and July 19, the company stated in an exchange filing. The USFDA has now issued an EIR for the facility, classifying it as ‘Voluntary Action Indicated’ (VAI). Shares of Zydus Lifesciences Ltd gained nearly ...
Zydus receives USFDA approval for ZITUVIO™ to treat adult …
WEBOct 20, 2023 — News provided by. Zydus Lifesciences Limited. Oct 20, 2023, 10:49 ET. Share this article. The company received final approval from the USFDA for its New Drug Application (NDA) for ZITUVIO™...
Zydus aims to launch first new drug in US by early 2026
WEBFeb 27, 2024 — India's Zydus Lifesciences is aiming to launch its first new drug in the United States by early 2026, looking to tap into the multi-billion dollar market for treating a type of liver disease,...
Zydus ties up with CSIR-CDRI to develop drug for CKD-induced ...
WEB5 days ago — Updated On Sep 28, 2024 at 12:56 PM IST. New Delhi: Zydus Lifesciences on Friday said it has tied up with Lucknow-based CSIR-Central Drug Research Institute (CDRI) to develop a drug for chronic ...
Zydus Group Latest Update, News And Press Releases - Zydus Life
WEB29 October 2021. zydus announces ‘first patient’ randomised in EVIDENCES-X TM Phase II (b) clinical trial of Saroglitazar Mg in NASH. 22 October 2021. Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate. 08 October 2021.